Interleukin-12
Summary Interleukin (IL)-12 is a heterodimeric cytokine produced by phagocytic cells, T cells and other antigen-presenting cells, mostly in response to bacteria, bacterial products and intracellular parasites. IL-12 is active on T cells and natural killer cells, inducing production of cytokines, pro...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Trinchieri, Giorgio [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
1995 |
|---|
| Schlagwörter: |
|---|
| Übergeordnetes Werk: |
Enthalten in: BioDrugs - Berlin [u.a.] : Springer, 1997, 3(1995), 4 vom: Apr., Seite 262-270 |
|---|---|
| Übergeordnetes Werk: |
volume:3 ; year:1995 ; number:4 ; month:04 ; pages:262-270 |
| Links: |
|---|
| DOI / URN: |
10.1007/BF03259278 |
|---|
| Katalog-ID: |
SPR032977735 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR032977735 | ||
| 003 | DE-627 | ||
| 005 | 20230519224641.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 201007s1995 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/BF03259278 |2 doi | |
| 035 | |a (DE-627)SPR032977735 | ||
| 035 | |a (SPR)BF03259278-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q ASE |
| 100 | 1 | |a Trinchieri, Giorgio |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Interleukin-12 |
| 264 | 1 | |c 1995 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Summary Interleukin (IL)-12 is a heterodimeric cytokine produced by phagocytic cells, T cells and other antigen-presenting cells, mostly in response to bacteria, bacterial products and intracellular parasites. IL-12 is active on T cells and natural killer cells, inducing production of cytokines, proliferation and enhancement of cytotoxic activity. Early during infections, IL-12 production induces interferon-γ (IFNγ), which in turn activates phagocytic cells and enhances their bacteriological activity. IL-12 and IFNγ also direct the development of T helper type 1 ($ T_{H} $1) cells, which produce interleukin-2 and IFNγ and activate cell-mediated resistance mechanisms against many pathogens. In several experimental models of infection, treatment with recombinant IL-12 has been shown to increase the immune resistance against infection. IL-12 is also an effective adjuvant in vaccines, favouring the development of protective $ T_{H} $1 memory responses. The ability of IL-12 to enhance the cellular immune response also makes it an effective agent for boosting the immune resistance against tumours. Thus, IL-12 has clinical potential as a therapeutic agent in infectious diseases and cancer. The immunopotentiating activity of IL-12, and the fact that cells from HIV-positive patients have a decreased ability to produce this cytokine, suggest the possible clinical use of IL-12 in AIDS therapy. | ||
| 650 | 4 | |a Adis International Limited |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Cutaneous Leishmaniasis |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Heterodimeric Cytokine |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Shwartzman Reaction |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Natural Killer Cell Stimulatory Factor |7 (dpeaa)DE-He213 | |
| 773 | 0 | 8 | |i Enthalten in |t BioDrugs |d Berlin [u.a.] : Springer, 1997 |g 3(1995), 4 vom: Apr., Seite 262-270 |w (DE-627)327644672 |w (DE-600)2043743-2 |x 1179-190X |7 nnns |
| 773 | 1 | 8 | |g volume:3 |g year:1995 |g number:4 |g month:04 |g pages:262-270 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1007/BF03259278 |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_SPRINGER | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a SSG-OPC-PHA | ||
| 912 | |a SSG-OPC-ASE | ||
| 951 | |a AR | ||
| 952 | |d 3 |j 1995 |e 4 |c 04 |h 262-270 | ||
| author_variant |
g t gt |
|---|---|
| matchkey_str |
article:1179190X:1995----::nelu |
| hierarchy_sort_str |
1995 |
| publishDate |
1995 |
| allfields |
10.1007/BF03259278 doi (DE-627)SPR032977735 (SPR)BF03259278-e DE-627 ger DE-627 rakwb eng 610 ASE Trinchieri, Giorgio verfasserin aut Interleukin-12 1995 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Summary Interleukin (IL)-12 is a heterodimeric cytokine produced by phagocytic cells, T cells and other antigen-presenting cells, mostly in response to bacteria, bacterial products and intracellular parasites. IL-12 is active on T cells and natural killer cells, inducing production of cytokines, proliferation and enhancement of cytotoxic activity. Early during infections, IL-12 production induces interferon-γ (IFNγ), which in turn activates phagocytic cells and enhances their bacteriological activity. IL-12 and IFNγ also direct the development of T helper type 1 ($ T_{H} $1) cells, which produce interleukin-2 and IFNγ and activate cell-mediated resistance mechanisms against many pathogens. In several experimental models of infection, treatment with recombinant IL-12 has been shown to increase the immune resistance against infection. IL-12 is also an effective adjuvant in vaccines, favouring the development of protective $ T_{H} $1 memory responses. The ability of IL-12 to enhance the cellular immune response also makes it an effective agent for boosting the immune resistance against tumours. Thus, IL-12 has clinical potential as a therapeutic agent in infectious diseases and cancer. The immunopotentiating activity of IL-12, and the fact that cells from HIV-positive patients have a decreased ability to produce this cytokine, suggest the possible clinical use of IL-12 in AIDS therapy. Adis International Limited (dpeaa)DE-He213 Cutaneous Leishmaniasis (dpeaa)DE-He213 Heterodimeric Cytokine (dpeaa)DE-He213 Shwartzman Reaction (dpeaa)DE-He213 Natural Killer Cell Stimulatory Factor (dpeaa)DE-He213 Enthalten in BioDrugs Berlin [u.a.] : Springer, 1997 3(1995), 4 vom: Apr., Seite 262-270 (DE-627)327644672 (DE-600)2043743-2 1179-190X nnns volume:3 year:1995 number:4 month:04 pages:262-270 https://dx.doi.org/10.1007/BF03259278 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA SSG-OPC-PHA SSG-OPC-ASE AR 3 1995 4 04 262-270 |
| spelling |
10.1007/BF03259278 doi (DE-627)SPR032977735 (SPR)BF03259278-e DE-627 ger DE-627 rakwb eng 610 ASE Trinchieri, Giorgio verfasserin aut Interleukin-12 1995 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Summary Interleukin (IL)-12 is a heterodimeric cytokine produced by phagocytic cells, T cells and other antigen-presenting cells, mostly in response to bacteria, bacterial products and intracellular parasites. IL-12 is active on T cells and natural killer cells, inducing production of cytokines, proliferation and enhancement of cytotoxic activity. Early during infections, IL-12 production induces interferon-γ (IFNγ), which in turn activates phagocytic cells and enhances their bacteriological activity. IL-12 and IFNγ also direct the development of T helper type 1 ($ T_{H} $1) cells, which produce interleukin-2 and IFNγ and activate cell-mediated resistance mechanisms against many pathogens. In several experimental models of infection, treatment with recombinant IL-12 has been shown to increase the immune resistance against infection. IL-12 is also an effective adjuvant in vaccines, favouring the development of protective $ T_{H} $1 memory responses. The ability of IL-12 to enhance the cellular immune response also makes it an effective agent for boosting the immune resistance against tumours. Thus, IL-12 has clinical potential as a therapeutic agent in infectious diseases and cancer. The immunopotentiating activity of IL-12, and the fact that cells from HIV-positive patients have a decreased ability to produce this cytokine, suggest the possible clinical use of IL-12 in AIDS therapy. Adis International Limited (dpeaa)DE-He213 Cutaneous Leishmaniasis (dpeaa)DE-He213 Heterodimeric Cytokine (dpeaa)DE-He213 Shwartzman Reaction (dpeaa)DE-He213 Natural Killer Cell Stimulatory Factor (dpeaa)DE-He213 Enthalten in BioDrugs Berlin [u.a.] : Springer, 1997 3(1995), 4 vom: Apr., Seite 262-270 (DE-627)327644672 (DE-600)2043743-2 1179-190X nnns volume:3 year:1995 number:4 month:04 pages:262-270 https://dx.doi.org/10.1007/BF03259278 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA SSG-OPC-PHA SSG-OPC-ASE AR 3 1995 4 04 262-270 |
| allfields_unstemmed |
10.1007/BF03259278 doi (DE-627)SPR032977735 (SPR)BF03259278-e DE-627 ger DE-627 rakwb eng 610 ASE Trinchieri, Giorgio verfasserin aut Interleukin-12 1995 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Summary Interleukin (IL)-12 is a heterodimeric cytokine produced by phagocytic cells, T cells and other antigen-presenting cells, mostly in response to bacteria, bacterial products and intracellular parasites. IL-12 is active on T cells and natural killer cells, inducing production of cytokines, proliferation and enhancement of cytotoxic activity. Early during infections, IL-12 production induces interferon-γ (IFNγ), which in turn activates phagocytic cells and enhances their bacteriological activity. IL-12 and IFNγ also direct the development of T helper type 1 ($ T_{H} $1) cells, which produce interleukin-2 and IFNγ and activate cell-mediated resistance mechanisms against many pathogens. In several experimental models of infection, treatment with recombinant IL-12 has been shown to increase the immune resistance against infection. IL-12 is also an effective adjuvant in vaccines, favouring the development of protective $ T_{H} $1 memory responses. The ability of IL-12 to enhance the cellular immune response also makes it an effective agent for boosting the immune resistance against tumours. Thus, IL-12 has clinical potential as a therapeutic agent in infectious diseases and cancer. The immunopotentiating activity of IL-12, and the fact that cells from HIV-positive patients have a decreased ability to produce this cytokine, suggest the possible clinical use of IL-12 in AIDS therapy. Adis International Limited (dpeaa)DE-He213 Cutaneous Leishmaniasis (dpeaa)DE-He213 Heterodimeric Cytokine (dpeaa)DE-He213 Shwartzman Reaction (dpeaa)DE-He213 Natural Killer Cell Stimulatory Factor (dpeaa)DE-He213 Enthalten in BioDrugs Berlin [u.a.] : Springer, 1997 3(1995), 4 vom: Apr., Seite 262-270 (DE-627)327644672 (DE-600)2043743-2 1179-190X nnns volume:3 year:1995 number:4 month:04 pages:262-270 https://dx.doi.org/10.1007/BF03259278 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA SSG-OPC-PHA SSG-OPC-ASE AR 3 1995 4 04 262-270 |
| allfieldsGer |
10.1007/BF03259278 doi (DE-627)SPR032977735 (SPR)BF03259278-e DE-627 ger DE-627 rakwb eng 610 ASE Trinchieri, Giorgio verfasserin aut Interleukin-12 1995 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Summary Interleukin (IL)-12 is a heterodimeric cytokine produced by phagocytic cells, T cells and other antigen-presenting cells, mostly in response to bacteria, bacterial products and intracellular parasites. IL-12 is active on T cells and natural killer cells, inducing production of cytokines, proliferation and enhancement of cytotoxic activity. Early during infections, IL-12 production induces interferon-γ (IFNγ), which in turn activates phagocytic cells and enhances their bacteriological activity. IL-12 and IFNγ also direct the development of T helper type 1 ($ T_{H} $1) cells, which produce interleukin-2 and IFNγ and activate cell-mediated resistance mechanisms against many pathogens. In several experimental models of infection, treatment with recombinant IL-12 has been shown to increase the immune resistance against infection. IL-12 is also an effective adjuvant in vaccines, favouring the development of protective $ T_{H} $1 memory responses. The ability of IL-12 to enhance the cellular immune response also makes it an effective agent for boosting the immune resistance against tumours. Thus, IL-12 has clinical potential as a therapeutic agent in infectious diseases and cancer. The immunopotentiating activity of IL-12, and the fact that cells from HIV-positive patients have a decreased ability to produce this cytokine, suggest the possible clinical use of IL-12 in AIDS therapy. Adis International Limited (dpeaa)DE-He213 Cutaneous Leishmaniasis (dpeaa)DE-He213 Heterodimeric Cytokine (dpeaa)DE-He213 Shwartzman Reaction (dpeaa)DE-He213 Natural Killer Cell Stimulatory Factor (dpeaa)DE-He213 Enthalten in BioDrugs Berlin [u.a.] : Springer, 1997 3(1995), 4 vom: Apr., Seite 262-270 (DE-627)327644672 (DE-600)2043743-2 1179-190X nnns volume:3 year:1995 number:4 month:04 pages:262-270 https://dx.doi.org/10.1007/BF03259278 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA SSG-OPC-PHA SSG-OPC-ASE AR 3 1995 4 04 262-270 |
| allfieldsSound |
10.1007/BF03259278 doi (DE-627)SPR032977735 (SPR)BF03259278-e DE-627 ger DE-627 rakwb eng 610 ASE Trinchieri, Giorgio verfasserin aut Interleukin-12 1995 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Summary Interleukin (IL)-12 is a heterodimeric cytokine produced by phagocytic cells, T cells and other antigen-presenting cells, mostly in response to bacteria, bacterial products and intracellular parasites. IL-12 is active on T cells and natural killer cells, inducing production of cytokines, proliferation and enhancement of cytotoxic activity. Early during infections, IL-12 production induces interferon-γ (IFNγ), which in turn activates phagocytic cells and enhances their bacteriological activity. IL-12 and IFNγ also direct the development of T helper type 1 ($ T_{H} $1) cells, which produce interleukin-2 and IFNγ and activate cell-mediated resistance mechanisms against many pathogens. In several experimental models of infection, treatment with recombinant IL-12 has been shown to increase the immune resistance against infection. IL-12 is also an effective adjuvant in vaccines, favouring the development of protective $ T_{H} $1 memory responses. The ability of IL-12 to enhance the cellular immune response also makes it an effective agent for boosting the immune resistance against tumours. Thus, IL-12 has clinical potential as a therapeutic agent in infectious diseases and cancer. The immunopotentiating activity of IL-12, and the fact that cells from HIV-positive patients have a decreased ability to produce this cytokine, suggest the possible clinical use of IL-12 in AIDS therapy. Adis International Limited (dpeaa)DE-He213 Cutaneous Leishmaniasis (dpeaa)DE-He213 Heterodimeric Cytokine (dpeaa)DE-He213 Shwartzman Reaction (dpeaa)DE-He213 Natural Killer Cell Stimulatory Factor (dpeaa)DE-He213 Enthalten in BioDrugs Berlin [u.a.] : Springer, 1997 3(1995), 4 vom: Apr., Seite 262-270 (DE-627)327644672 (DE-600)2043743-2 1179-190X nnns volume:3 year:1995 number:4 month:04 pages:262-270 https://dx.doi.org/10.1007/BF03259278 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA SSG-OPC-PHA SSG-OPC-ASE AR 3 1995 4 04 262-270 |
| language |
English |
| source |
Enthalten in BioDrugs 3(1995), 4 vom: Apr., Seite 262-270 volume:3 year:1995 number:4 month:04 pages:262-270 |
| sourceStr |
Enthalten in BioDrugs 3(1995), 4 vom: Apr., Seite 262-270 volume:3 year:1995 number:4 month:04 pages:262-270 |
| format_phy_str_mv |
Article |
| institution |
findex.gbv.de |
| topic_facet |
Adis International Limited Cutaneous Leishmaniasis Heterodimeric Cytokine Shwartzman Reaction Natural Killer Cell Stimulatory Factor |
| dewey-raw |
610 |
| isfreeaccess_bool |
false |
| container_title |
BioDrugs |
| authorswithroles_txt_mv |
Trinchieri, Giorgio @@aut@@ |
| publishDateDaySort_date |
1995-04-01T00:00:00Z |
| hierarchy_top_id |
327644672 |
| dewey-sort |
3610 |
| id |
SPR032977735 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">SPR032977735</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230519224641.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">201007s1995 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1007/BF03259278</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)SPR032977735</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(SPR)BF03259278-e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">ASE</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Trinchieri, Giorgio</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Interleukin-12</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">1995</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Summary Interleukin (IL)-12 is a heterodimeric cytokine produced by phagocytic cells, T cells and other antigen-presenting cells, mostly in response to bacteria, bacterial products and intracellular parasites. IL-12 is active on T cells and natural killer cells, inducing production of cytokines, proliferation and enhancement of cytotoxic activity. Early during infections, IL-12 production induces interferon-γ (IFNγ), which in turn activates phagocytic cells and enhances their bacteriological activity. IL-12 and IFNγ also direct the development of T helper type 1 ($ T_{H} $1) cells, which produce interleukin-2 and IFNγ and activate cell-mediated resistance mechanisms against many pathogens. In several experimental models of infection, treatment with recombinant IL-12 has been shown to increase the immune resistance against infection. IL-12 is also an effective adjuvant in vaccines, favouring the development of protective $ T_{H} $1 memory responses. The ability of IL-12 to enhance the cellular immune response also makes it an effective agent for boosting the immune resistance against tumours. Thus, IL-12 has clinical potential as a therapeutic agent in infectious diseases and cancer. The immunopotentiating activity of IL-12, and the fact that cells from HIV-positive patients have a decreased ability to produce this cytokine, suggest the possible clinical use of IL-12 in AIDS therapy.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Adis International Limited</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Cutaneous Leishmaniasis</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Heterodimeric Cytokine</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Shwartzman Reaction</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Natural Killer Cell Stimulatory Factor</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">BioDrugs</subfield><subfield code="d">Berlin [u.a.] : Springer, 1997</subfield><subfield code="g">3(1995), 4 vom: Apr., Seite 262-270</subfield><subfield code="w">(DE-627)327644672</subfield><subfield code="w">(DE-600)2043743-2</subfield><subfield code="x">1179-190X</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:3</subfield><subfield code="g">year:1995</subfield><subfield code="g">number:4</subfield><subfield code="g">month:04</subfield><subfield code="g">pages:262-270</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://dx.doi.org/10.1007/BF03259278</subfield><subfield code="z">lizenzpflichtig</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_SPRINGER</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OPC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OPC-ASE</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">3</subfield><subfield code="j">1995</subfield><subfield code="e">4</subfield><subfield code="c">04</subfield><subfield code="h">262-270</subfield></datafield></record></collection>
|
| author |
Trinchieri, Giorgio |
| spellingShingle |
Trinchieri, Giorgio ddc 610 misc Adis International Limited misc Cutaneous Leishmaniasis misc Heterodimeric Cytokine misc Shwartzman Reaction misc Natural Killer Cell Stimulatory Factor Interleukin-12 |
| authorStr |
Trinchieri, Giorgio |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)327644672 |
| format |
electronic Article |
| dewey-ones |
610 - Medicine & health |
| delete_txt_mv |
keep |
| author_role |
aut |
| collection |
springer |
| remote_str |
true |
| illustrated |
Not Illustrated |
| issn |
1179-190X |
| topic_title |
610 ASE Interleukin-12 Adis International Limited (dpeaa)DE-He213 Cutaneous Leishmaniasis (dpeaa)DE-He213 Heterodimeric Cytokine (dpeaa)DE-He213 Shwartzman Reaction (dpeaa)DE-He213 Natural Killer Cell Stimulatory Factor (dpeaa)DE-He213 |
| topic |
ddc 610 misc Adis International Limited misc Cutaneous Leishmaniasis misc Heterodimeric Cytokine misc Shwartzman Reaction misc Natural Killer Cell Stimulatory Factor |
| topic_unstemmed |
ddc 610 misc Adis International Limited misc Cutaneous Leishmaniasis misc Heterodimeric Cytokine misc Shwartzman Reaction misc Natural Killer Cell Stimulatory Factor |
| topic_browse |
ddc 610 misc Adis International Limited misc Cutaneous Leishmaniasis misc Heterodimeric Cytokine misc Shwartzman Reaction misc Natural Killer Cell Stimulatory Factor |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
cr |
| hierarchy_parent_title |
BioDrugs |
| hierarchy_parent_id |
327644672 |
| dewey-tens |
610 - Medicine & health |
| hierarchy_top_title |
BioDrugs |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)327644672 (DE-600)2043743-2 |
| title |
Interleukin-12 |
| ctrlnum |
(DE-627)SPR032977735 (SPR)BF03259278-e |
| title_full |
Interleukin-12 |
| author_sort |
Trinchieri, Giorgio |
| journal |
BioDrugs |
| journalStr |
BioDrugs |
| lang_code |
eng |
| isOA_bool |
false |
| dewey-hundreds |
600 - Technology |
| recordtype |
marc |
| publishDateSort |
1995 |
| contenttype_str_mv |
txt |
| container_start_page |
262 |
| author_browse |
Trinchieri, Giorgio |
| container_volume |
3 |
| class |
610 ASE |
| format_se |
Elektronische Aufsätze |
| author-letter |
Trinchieri, Giorgio |
| doi_str_mv |
10.1007/BF03259278 |
| dewey-full |
610 |
| title_sort |
interleukin-12 |
| title_auth |
Interleukin-12 |
| abstract |
Summary Interleukin (IL)-12 is a heterodimeric cytokine produced by phagocytic cells, T cells and other antigen-presenting cells, mostly in response to bacteria, bacterial products and intracellular parasites. IL-12 is active on T cells and natural killer cells, inducing production of cytokines, proliferation and enhancement of cytotoxic activity. Early during infections, IL-12 production induces interferon-γ (IFNγ), which in turn activates phagocytic cells and enhances their bacteriological activity. IL-12 and IFNγ also direct the development of T helper type 1 ($ T_{H} $1) cells, which produce interleukin-2 and IFNγ and activate cell-mediated resistance mechanisms against many pathogens. In several experimental models of infection, treatment with recombinant IL-12 has been shown to increase the immune resistance against infection. IL-12 is also an effective adjuvant in vaccines, favouring the development of protective $ T_{H} $1 memory responses. The ability of IL-12 to enhance the cellular immune response also makes it an effective agent for boosting the immune resistance against tumours. Thus, IL-12 has clinical potential as a therapeutic agent in infectious diseases and cancer. The immunopotentiating activity of IL-12, and the fact that cells from HIV-positive patients have a decreased ability to produce this cytokine, suggest the possible clinical use of IL-12 in AIDS therapy. |
| abstractGer |
Summary Interleukin (IL)-12 is a heterodimeric cytokine produced by phagocytic cells, T cells and other antigen-presenting cells, mostly in response to bacteria, bacterial products and intracellular parasites. IL-12 is active on T cells and natural killer cells, inducing production of cytokines, proliferation and enhancement of cytotoxic activity. Early during infections, IL-12 production induces interferon-γ (IFNγ), which in turn activates phagocytic cells and enhances their bacteriological activity. IL-12 and IFNγ also direct the development of T helper type 1 ($ T_{H} $1) cells, which produce interleukin-2 and IFNγ and activate cell-mediated resistance mechanisms against many pathogens. In several experimental models of infection, treatment with recombinant IL-12 has been shown to increase the immune resistance against infection. IL-12 is also an effective adjuvant in vaccines, favouring the development of protective $ T_{H} $1 memory responses. The ability of IL-12 to enhance the cellular immune response also makes it an effective agent for boosting the immune resistance against tumours. Thus, IL-12 has clinical potential as a therapeutic agent in infectious diseases and cancer. The immunopotentiating activity of IL-12, and the fact that cells from HIV-positive patients have a decreased ability to produce this cytokine, suggest the possible clinical use of IL-12 in AIDS therapy. |
| abstract_unstemmed |
Summary Interleukin (IL)-12 is a heterodimeric cytokine produced by phagocytic cells, T cells and other antigen-presenting cells, mostly in response to bacteria, bacterial products and intracellular parasites. IL-12 is active on T cells and natural killer cells, inducing production of cytokines, proliferation and enhancement of cytotoxic activity. Early during infections, IL-12 production induces interferon-γ (IFNγ), which in turn activates phagocytic cells and enhances their bacteriological activity. IL-12 and IFNγ also direct the development of T helper type 1 ($ T_{H} $1) cells, which produce interleukin-2 and IFNγ and activate cell-mediated resistance mechanisms against many pathogens. In several experimental models of infection, treatment with recombinant IL-12 has been shown to increase the immune resistance against infection. IL-12 is also an effective adjuvant in vaccines, favouring the development of protective $ T_{H} $1 memory responses. The ability of IL-12 to enhance the cellular immune response also makes it an effective agent for boosting the immune resistance against tumours. Thus, IL-12 has clinical potential as a therapeutic agent in infectious diseases and cancer. The immunopotentiating activity of IL-12, and the fact that cells from HIV-positive patients have a decreased ability to produce this cytokine, suggest the possible clinical use of IL-12 in AIDS therapy. |
| collection_details |
GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA SSG-OPC-PHA SSG-OPC-ASE |
| container_issue |
4 |
| title_short |
Interleukin-12 |
| url |
https://dx.doi.org/10.1007/BF03259278 |
| remote_bool |
true |
| ppnlink |
327644672 |
| mediatype_str_mv |
c |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| doi_str |
10.1007/BF03259278 |
| up_date |
2024-07-03T15:50:04.914Z |
| _version_ |
1803573584106356736 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">SPR032977735</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230519224641.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">201007s1995 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1007/BF03259278</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)SPR032977735</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(SPR)BF03259278-e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">ASE</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Trinchieri, Giorgio</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Interleukin-12</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">1995</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Summary Interleukin (IL)-12 is a heterodimeric cytokine produced by phagocytic cells, T cells and other antigen-presenting cells, mostly in response to bacteria, bacterial products and intracellular parasites. IL-12 is active on T cells and natural killer cells, inducing production of cytokines, proliferation and enhancement of cytotoxic activity. Early during infections, IL-12 production induces interferon-γ (IFNγ), which in turn activates phagocytic cells and enhances their bacteriological activity. IL-12 and IFNγ also direct the development of T helper type 1 ($ T_{H} $1) cells, which produce interleukin-2 and IFNγ and activate cell-mediated resistance mechanisms against many pathogens. In several experimental models of infection, treatment with recombinant IL-12 has been shown to increase the immune resistance against infection. IL-12 is also an effective adjuvant in vaccines, favouring the development of protective $ T_{H} $1 memory responses. The ability of IL-12 to enhance the cellular immune response also makes it an effective agent for boosting the immune resistance against tumours. Thus, IL-12 has clinical potential as a therapeutic agent in infectious diseases and cancer. The immunopotentiating activity of IL-12, and the fact that cells from HIV-positive patients have a decreased ability to produce this cytokine, suggest the possible clinical use of IL-12 in AIDS therapy.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Adis International Limited</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Cutaneous Leishmaniasis</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Heterodimeric Cytokine</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Shwartzman Reaction</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Natural Killer Cell Stimulatory Factor</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">BioDrugs</subfield><subfield code="d">Berlin [u.a.] : Springer, 1997</subfield><subfield code="g">3(1995), 4 vom: Apr., Seite 262-270</subfield><subfield code="w">(DE-627)327644672</subfield><subfield code="w">(DE-600)2043743-2</subfield><subfield code="x">1179-190X</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:3</subfield><subfield code="g">year:1995</subfield><subfield code="g">number:4</subfield><subfield code="g">month:04</subfield><subfield code="g">pages:262-270</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://dx.doi.org/10.1007/BF03259278</subfield><subfield code="z">lizenzpflichtig</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_SPRINGER</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OPC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OPC-ASE</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">3</subfield><subfield code="j">1995</subfield><subfield code="e">4</subfield><subfield code="c">04</subfield><subfield code="h">262-270</subfield></datafield></record></collection>
|
| score |
7.4000416 |